№ lp_2_1_33232
File format: docx
Character count: 43044
File size: 388 KB
Trust-wide policy outlining definitions, governance requirements, prescribing principles, responsibilities, consent arrangements and reporting procedures for the use of unlicensed and off-label medicines within clinical services.
Version number:
5.0
Date ratified:
July 2024
Implementation Date:
July 2024
Last Review Date:
July 2024
Next Review date:
July 2027
Approved by (Sponsor Group):
Medicines Committee
Ratified by:
Medicines Committee
Consultation Groups:
Medicines Committee; Community Health Service Policy Alignment Group
Name of originator/author:
Lead Pharmacist Tower Hamlets Community Health Service; Medicines Safety Officer
Executive Director lead:
Chief Medical Officer
Applicable services:
Trust wide
Related organisation:
East London NHS Foundation Trust
Regulatory authority referenced:
Medicines and Healthcare products Regulatory Agency
Subject:
Prescribing, supply and administration of unlicensed and off-label medicines
Scope:
All staff involved in prescribing and administration of unlicensed and off-label medicines
Review cycle:
Three years
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Wisconsin
Subject:
Child Placement
Document Type:
Form
Agency / Institution:
Wisconsin Department of Children and Families
Author:
Wisconsin Department of Children and Families
Target Audience:
Social Workers, Case Managers
Effective Period:
Indefinite
Approval Date:
2023
Amendment Date:
Not specified
Year:
Not specified
Region / City:
Not specified
Theme:
Nursing Care, Assisted Living
Document Type:
Policy
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Licensed Nurses, Unlicensed Assistive Personnel, Healthcare Providers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Program:
BEAD
Document Type:
Evidence Template Instructions and Schema
Purpose:
Guidance for completing the Unlicensed Fixed Wireless Service Evidence Template
Applicable Policy:
NTIA BEAD Restructuring Policy Notice
Issue Date:
June 6, 2025
Target Audience:
BEAD applicants
Submission Requirements:
All fields in Tabs 2–8 must be completed with supplemental evidence files
Content:
Network design assumptions, tower sites, sectors, BSLs, uplink/downlink MCS tables, logical network diagram
Technology Focus:
Unlicensed Fixed Wireless (ULFW)
Network Specifications:
Throughput, latency, coverage, oversubscription, RAN configurations, interference mitigation, system redundancy
Year:
2026
Region / city:
Washington
Topic:
Wireless Communication, IoT, AR/VR
Document Type:
Order
Organization / Institution:
Federal Communications Commission
Author:
Federal Communications Commission
Target Audience:
Industry professionals, consumers, wireless and IoT technology developers
Period of Action:
January 29, 2026
Approval Date:
January 29, 2026
Amendment Date:
N/A
Year:
2005
Region / City:
United Kingdom
Subject:
Gambling, Licensing
Document Type:
Application form, Official letter
Authority:
Gambling Commission
Author:
Licensing Authority
Target Audience:
Operators of family entertainment centres
Validity Period:
10 years
Approval Date:
N/A
Amendment Date:
N/A
Year:
2018
Date:
July 12, 2018
Region:
Brooklyn, New York, United States
Issuing Authority:
Federal Communications Commission, Enforcement Bureau, Region One, Columbia Regional Office
Case Number:
EB-FIELDNER-17-00023832
Addressee:
Rockaway154 LLC
Subject:
Unlicensed FM radio operation on 93.7 MHz
Legal Basis:
Section 301 of the Communications Act of 1934, as amended
Related Regulations:
Part 15 of the Commission’s Rules
Investigating Office:
New York Office, Enforcement Bureau
Investigating Date:
April 27, 2018
Signatory:
David C. Dombrowski, Regional Director, Region One
Attachments:
Excerpts from the Communications Act of 1934, As Amended; Enforcement Bureau “Inspection Fact Sheet”, March 2005
Year:
2018
Date:
September 19, 2018
Case Number:
EB-FIELDSCR-18-00026287
Issuing Authority:
Federal Communications Commission, Enforcement Bureau, Region Two, Atlanta Regional Office
Regional Director:
Ronald D. Ramage
Recipient:
Marques Dumerant
Location Investigated:
Delray Beach, Florida
Frequencies Involved:
91.7 MHz and 95.1 MHz
Legal Basis:
Section 301 of the Communications Act of 1934, as amended
Type of Document:
Enforcement Notice
Subject:
Unlicensed FM Radio Operation
Response Deadline:
Ten (10) days from date of notice
Attachments:
Excerpts from the Communications Act of 1934, As Amended; Enforcement Bureau "Inspection Fact Sheet," March 2005
Year:
2026
Region / City:
Stafford, UK
Subject:
Gambling / Licensing
Document Type:
Application Form
Issuing Authority:
Stafford Borough Council
Applicable Legislation:
Gambling Act 2005, Gaming Act 1968
Permit Type:
Unlicensed Family Entertainment Centre Gaming Machine Permit
Fee:
£300 for new grant, £100 for conversion, £25 for name change
Duration of Permit:
10 years
Eligibility:
Applicants 18 years or older
Submission Requirements:
Completed form, existing Section 34 permit (if applicable), applicable fee
Year:
1998
Region / City:
United States
Subject:
Deliberate misconduct by unlicensed individuals
Document Type:
Federal Register Notice
Organization / Institution:
U.S. Nuclear Regulatory Commission (NRC)
Author:
U.S. Nuclear Regulatory Commission
Target Audience:
Licensees, applicants, contractors, and subcontractors within the nuclear industry
Period of Action:
From 2/12/98
Approval Date:
2/12/98
Date of Modifications:
Not specified
Year:
2023
Location:
Xiamen, China
Subject:
5G NR sidelink carrier aggregation and unlicensed spectrum operation
Document type:
Technical contribution / meeting report
Organization:
3GPP TSG-RAN WG4
Author:
Huawei, HiSilicon
Agenda item:
5.30.2.1.2
Meeting number:
108bis
Target audience:
3GPP working group participants
Period:
October 09 – October 13, 2023
Related specifications:
NR Rel-16, Rel-17, Rel-18, TR38.886
Frequency bands:
FR1 licensed, n46, n47
Technical focus:
MPR evaluation, PSFCH resource allocation, carrier aggregation mechanism
Simulation parameters:
bandwidth, numerology, modulation, waveform, resource allocation, power calibration
Use cases:
V2X sidelink communications
Year:
2011
Region / City:
United States
Subject Area:
Medical research, hematology, transplantation
Document Type:
Informed consent form
Organization / Institution:
National Marrow Donor Program (NMDP), Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin
Principal Investigator:
<< Enter name/title of Principal Investigator>>
Sponsors / Funding:
NMDP/Be The Match, CIBMTR
Target Audience:
Patients undergoing cord blood transplant and their legal guardians
Study Period:
One year post-transplant
Date of Initiation:
October 2011
Procedures:
Cord blood infusion, medical data collection, post-transplant follow-up
Risks:
Infusion-related complications, infection risk, slow blood count recovery, potential unknown side effects
Alternatives:
Use of licensed cord blood units, transplant from unrelated donor, symptom-control treatment
Data Privacy:
Patient data labeled with number code, monitored for unauthorized access
Year:
2021
Organization:
3GPP TSG-RAN
Meeting:
WG1 Meeting #105-e
Document type:
Meeting Report / Technical Summary
Source:
Moderator (Ericsson)
Agenda item:
8.3.2
Target audience:
RAN1 members, telecom engineers
Discussion period:
May 10 – 27, 2021
Topics:
NR-U, URLLC, CG harmonization, HARQ processes, RRC parameters
Decisions:
Options for enabling/disabling CG-UCI and CG-DFI procedures for unlicensed bands
Observations:
Comparison of configuration options and company preferences
Year:
2023
Region / city:
Australia
Subject:
Pharmaceutical compounding guidelines
Document Type:
Guideline
Organization / Institution:
Pharmacy Board of Australia
Author:
Pharmacy Board of Australia
Target Audience:
Registered pharmacists, education providers, employers
Period of validity:
Indefinite
Approval Date:
Not specified
Date of amendments:
Not specified
Year:
2016
Region / City:
Australia
Topic:
Pharmacy, Medicine Compounding
Document Type:
Consultation Response
Organization:
Pharmaceutical Society of Australia
Author:
Dr Lance Emerson, Chief Executive Officer
Target Audience:
Pharmacists, Pharmacy Regulators
Period of Validity:
Indefinite
Approval Date:
1 February 2016
Date of Amendments:
None
Contextual Description:
Document is a public consultation response discussing terminology issues and proposed updates regarding compounded parenteral medicines, primarily aimed at Australian pharmacists.
Organisation:
Canberra Health Services
Document type:
Guideline
Reference number:
CHS25/225
Jurisdiction:
Australian Capital Territory
Healthcare setting:
Public health services
Subject area:
Medication management
Professional scope:
Nursing and midwifery practice
Approved by:
Drug and Therapeutics Committee
Target professionals:
Registered nurses and registered midwives
Patient groups:
Adults, children 12 years or older, and selected medicines for children under 12 years
Exclusions:
Neonates, Special Care Nursery patients, Neonatal Intensive Care Unit patients
Regulatory framework:
Australian medicines scheduling (Schedules 2, 3, 4, and 8)
Content components:
Governance, safe use, documentation, approved medicine lists
Year:
2023
Region / city:
European Union
Topic:
Pharmaceutical technology development
Document type:
Briefing document
Organization:
European Medicines Agency
Author:
Not specified
Target audience:
Pharmaceutical experts, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
Not specified
This document is a briefing source for discussing pharmaceutical technology and regulatory aspects at a QIG 1:
1 meeting.
Year:
2023
Country:
Australia
Topic:
Opioid dependence treatment
Document type:
Information overview
Program:
ODT Community Pharmacy Program
Administering body:
Pharmacy Programs Administrator
Related scheme:
Pharmaceutical Benefits Scheme
Legislative framework:
National Health (Highly specialised drugs program) Special Arrangement 2021
Target audience:
Community pharmacists and hospital pharmacists
Effective date:
1 July 2023
Funding period:
2023–24 to 2026–27
Medicines covered:
Methadone, buprenorphine, buprenorphine with naloxone
Regulatory classification:
Schedule 8 controlled drugs
Source type:
Government health program guidance
Document type:
Q&A guidance
Jurisdiction:
Japan
Subject:
Import and shipment of medicines and medical devices
Issuing authority:
Ministry of Health, Labour and Welfare
Intended users:
Individuals importing or sending medicines for personal use
Scope:
Prescription medicines, injections, syringes, and medical devices
Import purpose:
Personal use
Regulatory framework:
Pharmaceutical and Medical Device regulations
Application system:
Online Import Confirmation system
Related forms:
Import Confirmation Application Form (Form 12); Explanation of Pharmaceutical Product (Form 13)
Year:
2024
Region / city:
Denmark
Topic:
Medicine, Health Economics
Document type:
Template
Organization / institution:
Danish Medicines Council
Author:
Danish Medicines Council
Target audience:
Pharmaceutical companies
Period of validity:
Ongoing
Approval date:
10 September 2024
Date of changes:
1 April 2025
Version:
2.5